Quarterly ResultAug 13, 2026, 09:18 AM
ADC Therapeutics Q2 Net Loss $16.6M; FDA Raises Concerns on ZYNLONTA LOTIS-5
AI Summary
ADC Therapeutics reported a reduced net loss of $16.6 million for Q2 2026, down from $56.6 million in Q2 2025, with net product revenue slightly increasing to $18.6 million. The company announced that the FDA raised substantial concerns regarding the benefit-risk profile of ZYNLONTA in the LOTIS-5 trial, leading to an assessment of the regulatory path forward for full approval. Despite this, the LOTIS-7 trial completed enrollment with promising data, and a strategic reorganization resulted in a 17% workforce reduction and $10 million in annual cost savings. Cash and cash equivalents stood at $219.1 million as of June 30, 2026, with an expected runway into 2028.
Key Highlights
- FDA raised substantial concerns regarding ZYNLONTA LOTIS-5 trial's benefit-risk profile.
- Q2 2026 net loss significantly reduced to $16.6 million from $56.6 million in Q2 2025.
- Net product revenue for Q2 2026 increased to $18.6 million from $18.1 million YoY.
- Cash and cash equivalents were $219.1 million as of June 30, 2026, with runway into 2028.
- LOTIS-7 trial completed enrollment, data submitted to ASH, and Breakthrough Therapy designation planned.
- Strategic reorganization included a 17% workforce reduction, saving an estimated $10 million annually.
- Research and Development expense decreased to $17.4 million from $30.1 million YoY.
Price Impact
More from ADCT